Get started
Author

Lysanne A. Lievense

Observed names: L.A. Lievense, Lysanne A Lievense, Lysanne Lievense
OpenAlex ID: A5033203997
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2017 · Floris Dammeijer, Lysanne A. Lievense, et al. · Cancer Immunology Research · 142
PDF
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
2014 · Robin Cornelissen, Lysanne A. Lievense, et al. · PLoS ONE · 91
PDF
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression
2016 · Lysanne A. Lievense, Robin Cornelissen, et al. · Journal of Thoracic Oncology · 86
PDF
Checkpoint Blockade in Lung Cancer and Mesothelioma
2017 · Lysanne A. Lievense, Daniel H. Sterman, et al. · American Journal of Respiratory and Critical Care Medicine · 69
Tumor-associated macrophages in thoracic malignancies
2013 · L.A. Lievense, K. Bezemer, et al. · Lung Cancer · 60
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
2016 · Floris Dammeijer, Lysanne A. Lievense, et al. · Journal of Clinical Oncology · 50
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
2021 · Floris Dammeijer, Cornedine J. De Gooijer, et al. · EBioMedicine · 28
PDF
Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma
2015 · Robin Cornelissen, Lysanne A. Lievense, et al. · Lung Cancer · 27
Immunotherapy prospects in the treatment of lung cancer and mesothelioma.
2014 · Joachim G Aerts, Lysanne A Lievense, et al. · PubMed · 25
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients
2016 · Lysanne A. Lievense, Koen Bezemer, et al. · Lung Cancer · 20
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
2022 · Lysanne A. Lievense, Peter Heukels, et al. · JTO Clinical and Research Reports · 12
PDF
Dendritic Cell-Based Immunotherapy in Mesothelioma
2012 · Robin Cornelissen, Lysanne A Lievense, et al. · Immunotherapy · 11
Biomarkers for immune checkpoint inhibitors
2014 · Lysanne A Lievense, Joost P J J Hegmans, et al. · The Lancet Oncology · 9
Immune Therapy
2015 · Lysanne Lievense, Joachim Aerts, et al. · Advances in experimental medicine and biology · 2
Data from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Supplemental Figure Legends from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Supplementary Figures S1 through S7 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Data from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Supplementary Table 1 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
PDF
Supplementary Figures S1 through S7 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
PDF
Supplemental Figure Legends from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Supplementary Table 1 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023 · Floris Dammeijer, Lysanne A. Lievense, et al.
Personalized Immune Therapy
2017 · Joost Hegmans, Lysanne Lievense, et al.
Transcriptomics and proteomics in pleural diseases
2016 · Joost P. Hegmans, Lysanne A. Lievense, et al. · CRC Press eBooks
Works count: 25
Citation count: 634
H-index: 11
I10-index: 12
Year
Topic
Type